The Insight Partners Latest Research for Report “Pharmaceutical Fill and Finish Outsourcing Market Forecast to 2028″ Includes COVID-19 Impact and Global Analysis By State of Finished Products (Solids, Semi-Solids, and Liquids) and Content (Organic Substances Isolated from Animal Origin, Organic Substances Isolated from Microorganisms, and Inorganic Substances)
“Pharmaceutical Fill and Finish Outsourcing Market is projected to reach US$ 4,010.51 million by 2028 from US$ 2,657.04 million in 2021; it is expected to grow at a CAGR of 6.1% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Download PDF Sample Copy at:
The global pharmaceutical fill and finish outsourcing is more inclined towards contract manufacturing. There are several types of contract manufacturing for pharmaceuticals as well as for biotechnology products that involve partial contract manufacturing and complete manufacturing of pharmaceuticals and biotechnology products.
Top Companies Analysis:
The pharmaceutical fill and finish outsourcing market is majorly comprised of top players involving Abbott, Teva Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd, MabPlex International Ltd, Wockhardt, Cytovance Biologics, Thermo Fisher Scientific Inc. (Patheon N.V.), and Boehringer Ingelheim International GmbH.
The companies listed above are implementing various strategies that have resulted in the growth of the company and in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the pharmaceutical fill and finish outsourcing market:
July-2021: AbbVie announced the expansion of global operations with end-to-end drug substance and product supply for AbbVie CMO manufacturing partners. New AbbVie contract manufacturing services offerings include biologics, fill-finish, topical creams, and ointments, sterile ophthalmic ointments, and custom API.
October-2021: Boehringer Ingelheim announced receiving of Facility of the Year Award (FOYA) 2020 for the commercial facility in Shanghai for offering a leading R&D region characterized by strong innovative capacity for pharmaceutical engineering (PE).
With the onset of COVID-19, the demand for contract development and manufacturing organizations (CDMOs) services is skyrocketing, as CDMOs have stretched themselves to meet the needs of biopharmaceutical and pharmaceutical companies during the crisis. Contract Development and Manufacturing Organizations (CDMOs) offer fill and manufacturing services such as drug development and clinical supply, commercial active pharmaceutical ingredient (API) and drug manufacturing, and packaging to pharmaceutical companies. Such services allow pharmaceutical companies to reduce their development and manufacturing costs, timelines, and capital investments. The pre-pandemic situation resulted in trends wherein most pharma-CDMO relationships remained transactional. However, during the onset of the pandemic, the situation was reversed. Pharma companies suddenly faced challenges in producing millions of doses to match the unprecedented demand from the market. Therefore, the largest source of additional capacity was CDMOs. For instance, Pfizer, Moderna, and AstraZeneca officially announced their partnership with several CDMOs such as Catalent, Emergent Biosolutions, and Lonza after announcing significant expansions of their manufacturing plants.
Ask for Discount at:
Based on content, the pharmaceutical fill and finish outsourcing market is segmented into organic substances isolated from animal origin, organic substances isolated from microorganisms, and inorganic substances. The organic substances isolated from microorganism’s segment held the largest share of the market in 2020 and is projected to continue a similar trend during the forecast period. On the other hand, the organic substances isolated from the animal origin segment is estimated to register the second highest CAGR in the market during the forecast period. Currently, pharmaceutical companies are shifting their focus toward outsourcing companies for gaining their microbial manufacturing product expertise and launching their products from labs to market. This is primarily due to microbial-derived products carrying the second-largest market of biologics. For matching such unprecedented demand, there is a need for CDMOs microbial outsourcing.
Based on state of finished product, the pharmaceutical fill and finish outsourcing market is segmented into solids, semi-solids and liquids.
By content, the market is segmented into organic substances isolated from animal origin, organic substances isolated from microorganisms and inorganic substances.
Based on Geography, North America comprises of key countries such as United States, Canada, and Mexico. Additionally, Europe comprises of France, Germany, UK, Spain, Italy, and the Rest of Europe for analysis. Asia Pacific comprises of China, India, Japan, Australia, South Korea, and The Rest of APAC countries for analysis. MEA region comprises of Saudi Arabia, UAE, South Africa, and the Rest of MEA countries for analysis. Furthermore, South and Central America comprise of Brazil, Argentina, and the Rest of South and Central America countries.
Buy Report at:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi